Shaun Flint
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Shaun Flint has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
- Kenneth G. C. Smith
The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
4 shared publications C. Hogan
Department of Haematology, Royal Melbourne Hospital, Australia
2 shared publicationsD Yip
Department of Nephrology, Royal Melbourne Hospital
2 shared publications- Eoin F. McKinney
Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom
2 shared publications - James Christopher Lee
Francis Crick Institute, London, UK
2 shared publications - Marion Espéli
INSERM
2 shared publications
Latest Publications
- Open Access
- 28 June 2023
- Published by Wiley in European Journal of Immunology
- Vol. 53 (9) , e2250334
Transinteractome analysis reveals distinct niche requirements for isotype‐based plasma cell subsets in the bone marrow
Bone marrow (BM) long‐lived plasma cells (PCs) are essential for long‐term protection against infection, and their persistence within this organ relies on interactions with Cxcl12‐expressing stromal cells that are still not clearly identified. Here, using single cell RNAseq and in silico transinteractome analyses, we identified Leptin receptor positive (LepR+) mesenchymal cells as the stromal cell subset most likely to interact with PCs within the BM. Moreover, we demonstrated that depending on the isotype they express, PCs may use different sets of integrins and adhesion molecules to interact with these stromal cells. Altogether, our results constitute an unprecedented characterization of PC subset stromal niches and open new avenues for the specific targeting of BM PCs based on their isotype.
- 28 June 2023
- Published by Wiley in European Journal of Immunology
- Vol. 53 (9) , e2250334
Open AccessTransinteractome analysis reveals distinct niche requirements for isotype‐based plasma cell subsets in the bone marrow
Bone marrow (BM) long‐lived plasma cells (PCs) are essential for long‐term protection against infection, and their persistence within this organ relies on interactions with Cxcl12‐expressing stromal cells that are still not clearly identified. Here, using single cell RNAseq and in silico transinteractome analyses, we identified Leptin receptor positive (LepR+) mesenchymal cells as the stromal cell subset most likely to interact with PCs within the BM. Moreover, we demonstrated that depending on the isotype they express, PCs may use different sets of integrins and adhesion molecules to interact with these stromal cells. Altogether, our results constitute an unprecedented characterization of PC subset stromal niches and open new avenues for the specific targeting of BM PCs based on their isotype.
- Open Access
- 25 January 2019
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 13 (Supplement) , S037
DOP18 OSM neutralisation in IBD mucosal explant cultures reduces pro-inflammatory cytokine production
Oncostatin M (OSM) is a proinflammatory and profibrotic cytokine that has been implicated in the pathogenesis of inflammatory bowel disease (IBD). This is at least partly due to an ability to induce the secretion of cytokines and chemokines from intestinal stromal cells (West et al., Nat Med 2017). However, while mRNA expression is known to be elevated in inflamed bowel tissue from IBD patients, less is known about OSM protein levels and the effect of inhibiting OSM on cytokine production. The objective of this study was to measure OSM protein levels in serum and inflamed intestinal tissue from IBD patients, and to determine the effect of OSM neutralisation on cytokine production in an IBD mucosal explant model. Serum and involved intestinal mucosa from patients with active moderate/severe ulcerative colitis (UC) or Crohn’s disease, along with corresponding samples from healthy volunteers, were obtained with patient informed consent in accordance with ICH GCP under an ethics committee-approved protocol. For the gut explant model, IBD mucosal biopsies from each individual donor were cultured ex vivo for 24 h with either anti-OSM antibody (10 or 40 µg/ml), isotype control antibody or prednisolone (1 µM). Cytokine concentrations were measured in serum, tissue lysates, and explant culture supernatants by ELISA. OSM protein was significantly (p < 0.001) increased in serum from Crohn’s and UC patients compared with healthy volunteer samples and significantly (p < 0.05) elevated in intestinal tissue from Crohn’s and UC patients compared with healthy control samples. Incubation of human IBD intestinal explants with an anti-OSM antibody reduced spontaneous pro-inflammatory cytokine production. In the UC mucosal explant assay (n = 9 donors), 10 and 40 µg/ml anti-OSM treatment resulted in a mean 49% and 48% inhibition of IL1β, 36% and 57% inhibition of IL6, and 27% and 43% inhibition of TNFα production, respectively. In the Crohn’s mucosal explant assay (n = 13 donors), 10 and 40 µg/ml anti-OSM treatment resulted in a mean 51% and 64% inhibition of IL1β, 57% and 42% inhibition of IL6, and 31% and 37% inhibition of TNFα production, respectively. This degree of cytokine inhibition was greater than that shown for the isotype control. OSM protein is elevated in both serum and inflamed intestinal tissue from IBD patients. OSM neutralisation in the IBD mucosal explant assay reduced spontaneous pro-inflammatory cytokine production. Together these data support targeted approaches to modulating OSM for the treatment of UC and Crohn’s disease.
- 25 January 2019
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 13 (Supplement) , S037
Open AccessDOP18 OSM neutralisation in IBD mucosal explant cultures reduces pro-inflammatory cytokine production
Oncostatin M (OSM) is a proinflammatory and profibrotic cytokine that has been implicated in the pathogenesis of inflammatory bowel disease (IBD). This is at least partly due to an ability to induce the secretion of cytokines and chemokines from intestinal stromal cells (West et al., Nat Med 2017). However, while mRNA expression is known to be elevated in inflamed bowel tissue from IBD patients, less is known about OSM protein levels and the effect of inhibiting OSM on cytokine production. The objective of this study was to measure OSM protein levels in serum and inflamed intestinal tissue from IBD patients, and to determine the effect of OSM neutralisation on cytokine production in an IBD mucosal explant model. Serum and involved intestinal mucosa from patients with active moderate/severe ulcerative colitis (UC) or Crohn’s disease, along with corresponding samples from healthy volunteers, were obtained with patient informed consent in accordance with ICH GCP under an ethics committee-approved protocol. For the gut explant model, IBD mucosal biopsies from each individual donor were cultured ex vivo for 24 h with either anti-OSM antibody (10 or 40 µg/ml), isotype control antibody or prednisolone (1 µM). Cytokine concentrations were measured in serum, tissue lysates, and explant culture supernatants by ELISA. OSM protein was significantly (p < 0.001) increased in serum from Crohn’s and UC patients compared with healthy volunteer samples and significantly (p < 0.05) elevated in intestinal tissue from Crohn’s and UC patients compared with healthy control samples. Incubation of human IBD intestinal explants with an anti-OSM antibody reduced spontaneous pro-inflammatory cytokine production. In the UC mucosal explant assay (n = 9 donors), 10 and 40 µg/ml anti-OSM treatment resulted in a mean 49% and 48% inhibition of IL1β, 36% and 57% inhibition of IL6, and 27% and 43% inhibition of TNFα production, respectively. In the Crohn’s mucosal explant assay (n = 13 donors), 10 and 40 µg/ml anti-OSM treatment resulted in a mean 51% and 64% inhibition of IL1β, 57% and 42% inhibition of IL6, and 31% and 37% inhibition of TNFα production, respectively. This degree of cytokine inhibition was greater than that shown for the isotype control. OSM protein is elevated in both serum and inflamed intestinal tissue from IBD patients. OSM neutralisation in the IBD mucosal explant assay reduced spontaneous pro-inflammatory cytokine production. Together these data support targeted approaches to modulating OSM for the treatment of UC and Crohn’s disease.
- Open Access
- 28 March 2017
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 214 (4) , 1111-1128
Eros is a novel transmembrane protein that controls the phagocyte respiratory burst and is essential for innate immunity
The phagocyte respiratory burst is crucial for innate immunity. The transfer of electrons to oxygen is mediated by a membrane-bound heterodimer, comprising gp91phox and p22phox subunits. Deficiency of either subunit leads to severe immunodeficiency. We describe Eros (essential for reactive oxygen species), a protein encoded by the previously undefined mouse gene bc017643, and show that it is essential for host defense via the phagocyte NAPDH oxidase. Eros is required for expression of the NADPH oxidase components, gp91phox and p22phox. Consequently, Eros-deficient mice quickly succumb to infection. Eros also contributes to the formation of neutrophil extracellular traps (NETS) and impacts on the immune response to melanoma metastases. Eros is an ortholog of the plant protein Ycf4, which is necessary for expression of proteins of the photosynthetic photosystem 1 complex, itself also an NADPH oxio-reductase. We thus describe the key role of the previously uncharacterized protein Eros in host defense.
- 28 March 2017
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 214 (4) , 1111-1128
Open AccessEros is a novel transmembrane protein that controls the phagocyte respiratory burst and is essential for innate immunity
The phagocyte respiratory burst is crucial for innate immunity. The transfer of electrons to oxygen is mediated by a membrane-bound heterodimer, comprising gp91phox and p22phox subunits. Deficiency of either subunit leads to severe immunodeficiency. We describe Eros (essential for reactive oxygen species), a protein encoded by the previously undefined mouse gene bc017643, and show that it is essential for host defense via the phagocyte NAPDH oxidase. Eros is required for expression of the NADPH oxidase components, gp91phox and p22phox. Consequently, Eros-deficient mice quickly succumb to infection. Eros also contributes to the formation of neutrophil extracellular traps (NETS) and impacts on the immune response to melanoma metastases. Eros is an ortholog of the plant protein Ycf4, which is necessary for expression of proteins of the photosynthetic photosystem 1 complex, itself also an NADPH oxio-reductase. We thus describe the key role of the previously uncharacterized protein Eros in host defense.
- Open Access
- 1 December 2016
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 197 (11) , 4247-4256
Glucocorticoid-Induced Leucine Zipper Protein Controls Macropinocytosis in Dendritic Cells
Ag sampling is a key process in dendritic cell (DC) biology. DCs use constitutive macropinocytosis, receptor-mediated endocytosis, and phagocytosis to capture exogenous Ags for presentation to T cells. We investigated the mechanisms that regulate Ag uptake by DCs in the steady-state and after a short-term LPS exposure in vitro and in vivo. We show that the glucocorticoid-induced leucine zipper protein (GILZ), already known to regulate effector versus regulatory T cell activation by DCs, selectively limits macropinocytosis, but not receptor-mediated phagocytosis, in immature and recently activated DCs. In vivo, the GILZ-mediated inhibition of Ag uptake is restricted to the CD8α+ DC subset, which expresses the highest GILZ level among splenic DC subsets. In recently activated DCs, we further establish that GILZ limits p38 MAPK phosphorylation, providing a possible mechanism for GILZ-mediated macropinocytosis control. Finally, our results demonstrate that the modulation of Ag uptake by GILZ does not result in altered Ag presentation to CD4 T cells but impacts the efficiency of cross-presentation to CD8 T cells. Altogether, our results identify GILZ as an endogenous inhibitor of macropinocytosis in DCs, the action of which contributes to the fine-tuning of Ag cross-presentation.
- 1 December 2016
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 197 (11) , 4247-4256
Open AccessGlucocorticoid-Induced Leucine Zipper Protein Controls Macropinocytosis in Dendritic Cells
Ag sampling is a key process in dendritic cell (DC) biology. DCs use constitutive macropinocytosis, receptor-mediated endocytosis, and phagocytosis to capture exogenous Ags for presentation to T cells. We investigated the mechanisms that regulate Ag uptake by DCs in the steady-state and after a short-term LPS exposure in vitro and in vivo. We show that the glucocorticoid-induced leucine zipper protein (GILZ), already known to regulate effector versus regulatory T cell activation by DCs, selectively limits macropinocytosis, but not receptor-mediated phagocytosis, in immature and recently activated DCs. In vivo, the GILZ-mediated inhibition of Ag uptake is restricted to the CD8α+ DC subset, which expresses the highest GILZ level among splenic DC subsets. In recently activated DCs, we further establish that GILZ limits p38 MAPK phosphorylation, providing a possible mechanism for GILZ-mediated macropinocytosis control. Finally, our results demonstrate that the modulation of Ag uptake by GILZ does not result in altered Ag presentation to CD4 T cells but impacts the efficiency of cross-presentation to CD8 T cells. Altogether, our results identify GILZ as an endogenous inhibitor of macropinocytosis in DCs, the action of which contributes to the fine-tuning of Ag cross-presentation.
- Open Access
Leucocyte subset-specific type 1 interferon signatures in SLE and other immune-mediated diseases
Objectives: Type 1 interferons (IFN-1) are implicated in the pathogenesis of systemic lupus erythematosus (SLE), but most studies have only reported the effect of IFN-1 on mixed cell populations. We aimed to define modules of IFN-1-associated genes in purified leucocyte populations and use these as a basis for a detailed comparative analysis. Methods: CD4+ and CD8+ T cells, monocytes and neutrophils were purified from patients with SLE, other immune-mediated diseases and healthy volunteers and gene expression then determined by microarray. Modules of IFN-1-associated genes were defined using weighted gene coexpression network analysis. The composition and expression of these modules was analysed. Results: 1150 of 1288 IFN-1-associated genes were specific to myeloid subsets, compared with 11 genes unique to T cells. IFN-1 genes were more highly expressed in myeloid subsets compared with T cells. A subset of neutrophil samples from healthy volunteers (HV) and conditions not classically associated with IFN-1 signatures displayed increased IFN-1 gene expression, whereas upregulation of IFN-1-associated genes in T cells was restricted to SLE. Conclusions: Given the broad upregulation of IFN-1 genes in neutrophils including in some HV, investigators reporting IFN-1 signatures on the basis of whole blood samples should be cautious about interpreting this as evidence of bona fide IFN-1-mediated pathology. Instead, specific upregulation of IFN-1-associated genes in T cells may be a useful biomarker and a further mechanism by which elevated IFN-1 contributes to autoimmunity in SLE.
Open AccessLeucocyte subset-specific type 1 interferon signatures in SLE and other immune-mediated diseases
Objectives: Type 1 interferons (IFN-1) are implicated in the pathogenesis of systemic lupus erythematosus (SLE), but most studies have only reported the effect of IFN-1 on mixed cell populations. We aimed to define modules of IFN-1-associated genes in purified leucocyte populations and use these as a basis for a detailed comparative analysis. Methods: CD4+ and CD8+ T cells, monocytes and neutrophils were purified from patients with SLE, other immune-mediated diseases and healthy volunteers and gene expression then determined by microarray. Modules of IFN-1-associated genes were defined using weighted gene coexpression network analysis. The composition and expression of these modules was analysed. Results: 1150 of 1288 IFN-1-associated genes were specific to myeloid subsets, compared with 11 genes unique to T cells. IFN-1 genes were more highly expressed in myeloid subsets compared with T cells. A subset of neutrophil samples from healthy volunteers (HV) and conditions not classically associated with IFN-1 signatures displayed increased IFN-1 gene expression, whereas upregulation of IFN-1-associated genes in T cells was restricted to SLE. Conclusions: Given the broad upregulation of IFN-1 genes in neutrophils including in some HV, investigators reporting IFN-1 signatures on the basis of whole blood samples should be cautious about interpreting this as evidence of bona fide IFN-1-mediated pathology. Instead, specific upregulation of IFN-1-associated genes in T cells may be a useful biomarker and a further mechanism by which elevated IFN-1 contributes to autoimmunity in SLE.
- Top Cited PapersOpen Access
- 14 June 2014
- Published by American Diabetes Association in Diabetes
- Vol. 63 (7) , 2538-2550
A Type I Interferon Transcriptional Signature Precedes Autoimmunity in Children Genetically at Risk for Type 1 Diabetes
Diagnosis of the autoimmune disease type 1 diabetes (T1D) is preceded by the appearance of circulating autoantibodies to pancreatic islets. However, almost nothing is known about events leading to this islet autoimmunity. Previous epidemiological and genetic data have associated viral infections and antiviral type I interferon (IFN) immune response genes with T1D. Here, we first used DNA microarray analysis to identify IFN-β–inducible genes in vitro and then used this set of genes to define an IFN-inducible transcriptional signature in peripheral blood mononuclear cells from a group of active systemic lupus erythematosus patients (n = 25). Using this predefined set of 225 IFN signature genes, we investigated the expression of the signature in cohorts of healthy controls (n = 87), patients with T1D (n = 64), and a large longitudinal birth cohort of children genetically predisposed to T1D (n = 109; 454 microarrayed samples). Expression of the IFN signature was increased in genetically predisposed children before the development of autoantibodies (P = 0.0012) but not in patients with established T1D. Upregulation of IFN-inducible genes was transient, temporally associated with a recent history of upper respiratory tract infections (P = 0.0064), and marked by increased expression of SIGLEC-1 (CD169), a lectin-like receptor expressed on CD14+ monocytes. DNA variation in IFN-inducible genes altered T1D risk (P = 0.007), as exemplified by IFIH1, one of the genes in our IFN signature for which increased expression is a known risk factor for disease. These findings identify transient increased expression of type I IFN genes in preclinical diabetes as a risk factor for autoimmunity in children with a genetic predisposition to T1D.
- 14 June 2014
- Published by American Diabetes Association in Diabetes
- Vol. 63 (7) , 2538-2550
Top Cited PapersOpen AccessA Type I Interferon Transcriptional Signature Precedes Autoimmunity in Children Genetically at Risk for Type 1 Diabetes
Diagnosis of the autoimmune disease type 1 diabetes (T1D) is preceded by the appearance of circulating autoantibodies to pancreatic islets. However, almost nothing is known about events leading to this islet autoimmunity. Previous epidemiological and genetic data have associated viral infections and antiviral type I interferon (IFN) immune response genes with T1D. Here, we first used DNA microarray analysis to identify IFN-β–inducible genes in vitro and then used this set of genes to define an IFN-inducible transcriptional signature in peripheral blood mononuclear cells from a group of active systemic lupus erythematosus patients (n = 25). Using this predefined set of 225 IFN signature genes, we investigated the expression of the signature in cohorts of healthy controls (n = 87), patients with T1D (n = 64), and a large longitudinal birth cohort of children genetically predisposed to T1D (n = 109; 454 microarrayed samples). Expression of the IFN signature was increased in genetically predisposed children before the development of autoantibodies (P = 0.0012) but not in patients with established T1D. Upregulation of IFN-inducible genes was transient, temporally associated with a recent history of upper respiratory tract infections (P = 0.0064), and marked by increased expression of SIGLEC-1 (CD169), a lectin-like receptor expressed on CD14+ monocytes. DNA variation in IFN-inducible genes altered T1D risk (P = 0.007), as exemplified by IFIH1, one of the genes in our IFN signature for which increased expression is a known risk factor for disease. These findings identify transient increased expression of type I IFN genes in preclinical diabetes as a risk factor for autoimmunity in children with a genetic predisposition to T1D.
- Open Access
- 1 June 2013
- Published by Elsevier in Kidney International
- Vol. 83 (6) , 1150-1158
Leukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis
- 1 June 2013
- Published by Elsevier in Kidney International
- Vol. 83 (6) , 1150-1158
Open AccessLeukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis
- Open Access
- 1 March 2012
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 23 (3) , 378-380
Anti–LAMP-2 Autoantibodies in ANCA-Associated Pauci-Immune Glomerulonephritis
- 1 March 2012
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 23 (3) , 378-380
Open AccessAnti–LAMP-2 Autoantibodies in ANCA-Associated Pauci-Immune Glomerulonephritis
- Open Access
- 30 March 2011
- Published by Elsevier in American Journal of Transplantation
- Vol. 11 (5) , 1016-1024
Successful ABO-Incompatible Kidney Transplantation with Antibody Removal and Standard Immunosuppression
- 30 March 2011
- Published by Elsevier in American Journal of Transplantation
- Vol. 11 (5) , 1016-1024
Open AccessSuccessful ABO-Incompatible Kidney Transplantation with Antibody Removal and Standard Immunosuppression